Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine Fumarate for Prolonged Mechanical Ventilation Abirritation in the ICU
NCT07372924Phase 2Completed
- Sponsor
- Hengrui
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tegileridine in abirritation (3 arms), sponsored by Hengrui. Primary endpoint: Rate of abirritation success at 3 days. Started Feb 2026; status: completed.
02
Drugs
tegileridine
03
Conditions
abirritation
Beyond the preview
Go deeper on NCT07372924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372924.